

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 1 of 11


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**IN THE TITLE PAGES:**


In Item [56] References Cited, in OTHER PUBLICATIONS:  
in Venturoli et al., please replace "Prospective" with --Prospective--

**IN THE SPECIFICATION:**

At column 5, line 20, please replace structure



At column 9, line 34, please replace "A R<sup>9</sup>" with --R<sup>9</sup>--  
At column 31, line 56-67, please replace structure



UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.


Page 2 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**IN THE CLAIMS:**

Please replace Claims 1, 10, 24, 40, 57, and 58 with the following Claims:

1. A compound having the formula:



wherein:

R<sup>1</sup> is selected from the group consisting of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OR<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, S(O)<sub>n</sub>R<sup>9</sup>, optionally substituted C<sub>1</sub>-C<sub>8</sub> alkyl, optionally substituted C<sub>1</sub>-C<sub>8</sub> haloalkyl, optionally substituted C<sub>1</sub>-C<sub>8</sub> heteroalkyl, optionally substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C<sub>2</sub>-C<sub>8</sub> alkynyl and optionally substituted C<sub>2</sub>-C<sub>8</sub> alkenyl;

R<sup>2</sup> is selected from the group consisting of hydrogen, F, Cl, Br, I, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, CF<sub>2</sub>OR<sup>9</sup>, CH<sub>2</sub>OR<sup>9</sup>, OR<sup>9</sup>, S(O)<sub>n</sub>R<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, optionally substituted C<sub>1</sub>-C<sub>8</sub> alkyl, optionally substituted C<sub>1</sub>-C<sub>8</sub> haloalkyl, optionally substituted C<sub>1</sub>-C<sub>8</sub> heteroalkyl, optionally substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C<sub>2</sub>-C<sub>8</sub> alkynyl and optionally substituted C<sub>2</sub>-C<sub>8</sub> alkenyl;

R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group consisting of hydrogen, OR<sup>9</sup>, S(O)<sub>n</sub>R<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, C(Y)OR<sup>11</sup>, CNR<sup>10</sup>R<sup>11</sup>, optionally substituted C<sub>1</sub>-C<sub>8</sub> alkyl, optionally substituted C<sub>1</sub>-C<sub>8</sub> haloalkyl, optionally substituted C<sub>1</sub>-C<sub>8</sub> heteroalkyl, optionally substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C<sub>2</sub>-C<sub>8</sub> alkynyl and optionally substituted C<sub>2</sub>-C<sub>8</sub> alkenyl;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 3 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

$R^5$  and  $R^6$  each independently is selected from the group consisting of hydrogen,  $CF_3$ ,  $CF_2Cl$ ,  $CF_2H$ ,  $CFH_2$ , optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted  $C_2-C_8$  alkynyl and optionally substituted  $C_2-C_8$  alkenyl;

$R^7$  is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl,  $OR^9$ ,  $S(O)_nR^9$ ,  $NR^{10}R^{11}$ ,  $C(Y)OR^{11}$  and  $C(Y)NR^{10}R^{11}$ ;

$R^8$  is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl,  $OR^9$ ,  $S(O)_nR^9$ ,  $NR^{10}R^{11}$ ,  $C(Y)OR^{11}$  and  $C(Y)NR^{10}R^{11}$ ;

$R^9$  is selected from the group consisting of hydrogen, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted arylalkyl;

$R^{10}$  is selected from the group consisting of hydrogen, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl,  $CO_2R^{12}$ ,  $C(O)R^{12}$ ,  $SO_2R^{12}$  and  $S(O)R^{12}$ ;

$R^{11}$  and  $R^{12}$  each independently is selected from the group consisting of hydrogen, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

$R^{13}$  is selected from the group consisting of optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_2-C_8$  alkenyl, optionally substituted  $C_2-C_8$  alkynyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is selected from the group consisting of 0, 1 and 2;

n is selected from the group consisting of 0, 1 and 2;

W is selected from the group consisting of NH,  $N\{R^{13}\}$ ,  $N\{C(Y)R^{11}\}$  and  $N\{SO_2R^{11}\}$ ;

X is O;

Z is selected from the group consisting of NH,  $N\{R^{11}\}$ ,  $N\{C(Y)R^{11}\}$ ,  $N\{SO_2R^{12}\}$  and  $N\{S(O)R^{12}\}$ ; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 4 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkylthio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO<sub>2</sub>, NH<sub>2</sub>, N<sub>3</sub>, NHCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, SH, SCH<sub>3</sub>, OH, OCH<sub>3</sub>, OCF<sub>3</sub>, CH<sub>3</sub>, CF<sub>3</sub>, C(O)CH<sub>3</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>H, C(O)NH<sub>2</sub>, OR<sup>9</sup>, SR<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, CF<sub>2</sub>CF<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>F and CH<sub>2</sub>CF<sub>3</sub>. *Column 82, lines 6-54, Claim 10 should read*

10. The compound of claim 1, wherein:

R<sup>1</sup> is selected from the group consisting of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OR<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, S(O)<sub>n</sub>R<sup>9</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, aryl, arylalkyl, heteroaryl, C<sub>2</sub>-C<sub>8</sub> alkynyl and C<sub>2</sub>-C<sub>8</sub> alkenyl;

R<sup>2</sup> is selected from the group consisting of hydrogen, F, Cl, Br, I, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, CF<sub>2</sub>OR<sup>9</sup>, CH<sub>2</sub>OR<sup>9</sup>, OR<sup>9</sup>, S(O)<sub>n</sub>R<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, aryl, arylalkyl, heteroaryl, C<sub>2</sub>-C<sub>8</sub> alkynyl and C<sub>2</sub>-C<sub>8</sub> alkenyl;

R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group consisting of hydrogen, OR<sup>9</sup>, S(O)<sub>n</sub>R<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, C(Y)OR<sup>11</sup>, C(Y)NR<sup>10</sup>R<sup>11</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, aryl, arylalkyl, heteroaryl, C<sub>2</sub>-C<sub>8</sub> alkynyl and C<sub>2</sub>-C<sub>8</sub> alkenyl;

R<sup>5</sup> and R<sup>6</sup> each independently is selected from the group consisting of hydrogen, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, aryl, arylalkyl, heteroaryl, C<sub>2</sub>-C<sub>8</sub> alkynyl and C<sub>2</sub>-C<sub>8</sub> alkenyl;

R<sup>7</sup> is selected from the group consisting of hydrogen, F, Cl, Br, I, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, OR<sup>9</sup>, S(O)<sub>n</sub>R<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, C(Y)OR<sup>11</sup> and C(Y)NR<sup>10</sup>R<sup>11</sup>;

R<sup>8</sup> is selected from the group consisting of hydrogen, F, Cl, Br, I, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, OR<sup>9</sup>, S(O)<sub>n</sub>R<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, C(Y)OR<sup>11</sup> and C(Y)NR<sup>10</sup>R<sup>11</sup>;

R<sup>9</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl and arylalkyl;

R<sup>10</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, arylalkyl, CO<sub>2</sub>R<sup>12</sup>, C(O)R<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup> and S(O)R<sup>12</sup>;

R<sup>11</sup> and R<sup>12</sup> each independently is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, arylalkyl;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,214,690 B2  
 APPLICATION NO. : 10/080503  
 DATED : May 8, 2007  
 INVENTOR(S) : Higuchi et al.

Page 5 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

$R^{13}$  is selected from the group consisting of  $C_1-C_8$  alkyl,  $C_1-C_8$  haloalkyl,  $C_1-C_8$  heteroalkyl,  $C_2-C_8$  alkenyl,  $C_2-C_8$  alkynyl,  $C_3-C_8$  cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;

$m$  is selected from the group consisting of 0, 1 and 2;

$n$  is selected from the group consisting of 0, 1 and 2;

$W$  is selected from the group consisting of  $NH$ ,  $N\{R^{13}\}$ ,  $N\{C(Y)R^{11}\}$  and  $N\{SO_2R^{11}\}$ ;

$X$  is O;


$Z$  is selected from the group consisting of  $NH$ ,  $N\{R^{11}\}$ ,  $N\{C(Y)R^{11}\}$ ,  $N\{SO_2R^{12}\}$  and  $N\{S(O)R^{12}\}$ ; and

$Y$  is O;

and pharmaceutically acceptable salts thereof.

24. A compound according to claim 23, wherein  $R^9$  is selected from the group consisting of hydrogen and optionally substituted  $C_1-C_4$  alkyl.

40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



wherein:

$R^1$  is selected from the group consisting of hydrogen, F, Cl, Br, I,  $NO_2$ ,  $OR^9$ ,  $NR^{10}R^{11}$ ,  $S(O)_nR^9$ , optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted  $C_2-C_8$  alkynyl and optionally substituted  $C_2-C_8$  alkenyl;

$R^2$  is selected from the group consisting of hydrogen, F, Cl, Br, I,  $CF_3$ ,  $CF_2Cl$ ,  $CF_2H$ ,  $CFH_2$ ,  $CF_2OR^9$ ,  $CH_2OR^9$ ,  $OR^9$ ,  $S(O)_nR^9$ ,  $NR^{10}R^{11}$ , optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted  $C_2-C_8$  alkynyl and optionally substituted  $C_2-C_8$  alkenyl;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 6 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

$R^3$  and  $R^4$  each independently is selected from the group consisting of hydrogen,  $OR^9$ ,  $S(O)_nR^9$ ,  $NR^{10}R^{11}$ ,  $C(Y)OR^{11}$ ,  $C(Y)NR^{10}R^{11}$ , optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted  $C_2-C_8$  alkynyl and optionally substituted  $C_2-C_8$  alkenyl;

$R^5$  and  $R^6$  each independently are selected from the group consisting of hydrogen,  $CF_3$ ,  $CF_2Cl$ ,  $CF_2H$ ,  $CFH_2$ , optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted  $C_2-C_8$  alkynyl and optionally substituted  $C_2-C_8$  alkenyl;

$R^7$  is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl,  $OR^9$ ,  $S(O)_nR^9$ ,  $NR^{10}R^{11}$ ,  $C(Y)OR^{11}$  and  $C(Y)NR^{10}R^{11}$ ;

$R^8$  is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl,  $OR^9$ ,  $S(O)_nR^9$ ,  $NR^{10}R^{11}$ ,  $C(Y)OR^{11}$  and  $C(Y)NR^{10}R^{11}$ ;

$R^9$  is selected from the group consisting of hydrogen, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

$R^{10}$  is selected from the group consisting of hydrogen, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl,  $CO_2R^{12}$ ,  $C(O)R^{12}$ ,  $SO_2R^{12}$  and  $S(O)R^{12}$ ;

$R^{11}$  and  $R^{12}$  each independently is selected from the group consisting of hydrogen, optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

$R^{13}$  is selected from the group consisting of optionally substituted  $C_1-C_8$  alkyl, optionally substituted  $C_1-C_8$  haloalkyl, optionally substituted  $C_1-C_8$  heteroalkyl, optionally substituted  $C_2-C_8$  alkenyl, optionally substituted  $C_2-C_8$  alkynyl, optionally substituted  $C_3-C_8$  cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is 1;

n is selected from the group consisting of 0, 1 and 2;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 7 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

W is selected from the group consisting of NH, N{R<sup>13</sup>}, N{C(Y)R<sup>11</sup>} and N{SO<sub>2</sub>R<sup>11</sup>};

X is O;

Z is selected from the group consisting of NH, N{R<sup>11</sup>}, N{C(Y)R<sup>11</sup>}, N{SO<sub>2</sub>R<sup>12</sup>} and N{S(O)R<sup>12</sup>}; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkylthio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO<sub>2</sub>, NH<sub>2</sub>, N<sub>3</sub>, NHCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, SH, SCH<sub>3</sub>, OH, OCH<sub>3</sub>, OCF<sub>3</sub>, CH<sub>3</sub>, CF<sub>3</sub>, C(O)CH<sub>3</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>H, C(O)NH<sub>2</sub>, OR<sup>9</sup>, SR<sup>9</sup>, NR<sup>10</sup>R<sup>11</sup>, CF<sub>2</sub>CF<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>F and CH<sub>2</sub>CF<sub>3</sub>. *Column 88, line 27 thru Column 90, line 35, Claim 57 should read*  
57. A compound selected from the group consisting of:

(3R)-2,3,4,7-Tetrahydro-3-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-2,3,4,7-Tetrahydro-3,4-dimethyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-4-Ethyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-2,3,4,7-Tetrahydro-3-methyl-4-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-4-Allyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-3-Ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-3,4-Diethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 8 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(3R)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-Allyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-isobutyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R/S)-2,3,4,7-Tetrahydro-3-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R/S)-2,3,4,7-Tetrahydro-4-methyl-3-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R/S)-4-Ethyl-2,3,4,7-tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R/S)-2,3,4,7-Tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-4-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-Ethyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-Allyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-2,3,4,7-Tetrahydro-3-phenyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-2,3,4,7-Tetrahydro-3-phenyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-phenyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-3-Benzyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;



UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 9 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

2,3,4,7-Tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino  
[2,3-f]quinolin-8-one;  
(7aR,10aS)-7,7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl)  
-7-(2,2,2-trifluoroethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;  
(7aR,10aS)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl)  
-4H-cyclopenta-[5,6][1,4]oxazino[2,3-f]quinolin-3-one;  
(7aR,10aS)-7,7a,8,9,10,10a-Hexahydro-3-isopropoxy-1-(trifluoromethyl)  
-7-(2,2,2-trifluoroethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;  
(±)-(2S,3R)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl)  
-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(6aR)-6a,7,8,9-Tetrahydro-4-(trifluoromethyl)-1H,6H-pyrrolo[1',2':4,5][1,4]  
-oxazino[2,3-f]quinolin-2-one;  
2,3,4,7-Tetrahydro-2,2,4-trimethyl-10-(trifluoromethyl)-8H-[1,4]oxazino  
[2,3-f]-quinolin-8-one;  
(3R)-8-Chloro-3-ethyl-3,4-dihydro-8-isopropoxy-4-(2,2,2-trifluoroethyl)  
-10-(trifluoromethyl)-2H-[1,4]oxazino[2,3-f]quinoline;  
(3R)-3-Ethyl-3,4-dihydro-8-isopropoxy-8-methoxy-4-(2,2,2-trifluoroethyl)  
-10-(trifluoromethyl)-2H-[1,4]oxazino[2,3-f]quinoline;  
(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(-)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(±)-2,3,4,7-Tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]  
oxazino[2,3-f]quinolin-8-one;  
(±)-2,3,4,7-Tetrahydro-4-methyl-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(±)-4-Ethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(±)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(-)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(+)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 10 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-Cyclopropylmethyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2-Chloroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(±)-2,3,4,7-Tetrahydro-2-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-3-Ethyl-4-(2-hydroxy-2-methylpropyl)-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one; and  
(3R)-2,3,4,7-Tetrahydro-3-isobutyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one; and

pharmaceutically acceptable salts thereof.

58. A compound selected from the group consisting of:

(3R)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(3R)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(7aR,10aS)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;  
(7aR,10aS)-7-7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl)-7-(2,2,2-trifluoroethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;  
(±)-(2S,3R)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;  
(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

Column 90, line 35  
thru Column 92, line 58.  
Claim 58  
Should read

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,214,690 B2  
APPLICATION NO. : 10/080503  
DATED : May 8, 2007  
INVENTOR(S) : Higuchi et al.

Page 11 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(-)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-8-one; and  
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)  
-8H-[1,4]oxazino[2,3-f]quinolin-one; and  
pharmaceutically acceptable salts thereof.

This certificate supersedes certificate of correction  
issued June 17, 2008.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]